Veristat Featured Articles

1. Early Detection vs. Overdiagnosis: The ctDNA Screening Paradox 6/4/2026

   Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.

2. The ctDNA Clinical Trial Advantage 5/27/2026

   See how CROs are helping shape the future of ctDNA research—translating emerging data, regulatory insights, and biomarker innovation into faster, smarter oncology development.

3. Mergers And Acquisitions: How Institutional Knowledge Protecting Value 5/27/2026

   M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

4. Simultaneous Submissions And Managing Multiple Regulatory Pathways 5/27/2026

   Global regulators are increasingly aligned, creating new opportunities for sponsors to pursue near-simultaneous submissions across major markets

5. Rare Disease Development: Navigating Small Populations And Complex Protocols 5/22/2026

   Learn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.

6. The Compound Effect Of Specialized Knowledge 5/22/2026

   How does specialized knowledge compound over time into foresight, stronger execution, and more confident decision-making across the drug development lifecycle?

7. Measuring What Can't Be Seen: How PTSD Clinical Trials Prove A Drug Works 5/22/2026

   PTSD trials expose one of the hardest problems in modern drug development, a reliance on clinician-administered and patient-reported scales to determine whether a therapy truly works.

8. CMC Strategies For Cell And Gene Therapy Development 7/2/2025

   The regulatory environment for cell and gene therapies (CGTs) is evolving rapidly, requiring sponsors to adopt a more strategic, integrated development approach.

9. Project Optimus: Shifting Away From Maximum Tolerated Dose 7/2/2025

   Project Optimus represents a transformative shift in oncology, advocating for a more nuanced, evidence-based approach to dose selection, prioritizing patient safety alongside treatment effectiveness.

10. Bayesian Study Designs In Early-Phase Oncology Trials 5/23/2025

    In response to insufficient traditional dose-escalation methods, regulatory initiatives like the FDA’s Project Optimus advocate for identifying optimal biological doses rather than relying solely on maximum tolerated doses (MTD).